Several studies have evaluated the use of the Ki–67 proliferation index of a tumor during treatment as an independent prognostic tool for oncologic outcomes such as recurrence, death following recurrence, and relapse-free survival [4,17,18,19]. This evidence concerns the gene MKI67 and neoplasm.